Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study.

Saved in:
Bibliographic Details
Title: Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study.
Authors: Kawuma R; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda. rachel.kawuma@mrcuganda.org., Nakamanya S; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda., Tarimo E; Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania., Chimukuche RS; Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa.; Division of Infection & Immunity, University College London, London, UK., Ambindwile J; National Institute for Medical Research-Mbeya Medical Research Centre, Mbeya, Tanzania., Pamba D; National Institute for Medical Research-Mbeya Medical Research Centre, Mbeya, Tanzania., Kusemererwa S; Viral Pathogens and Epidemiology Interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda., Munseri P; Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania., Singh N; HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa., Dubé K; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA., McCormack S; MRC Clinical Trials Unit, University College London, London, UK., Ruzagira E; Viral Pathogens and Epidemiology Interventions, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK., Seeley J; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.; Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa.; Department of Global Health and Development, London School of Tropical Hygiene and Medicine, London, UK.
Corporate Authors: PrEPVacc trial team
Source: Trials [Trials] 2026 May 16; Vol. 27 (1). Date of Electronic Publication: 2026 May 16.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1745-6215
DOI:10.1186/s13063-026-09774-5